{
    "organizations": [],
    "uuid": "fcd31cac50a95e5a4c248a50390678254367792a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cellectar-biosciences-gets-granted/brief-cellectar-biosciences-gets-granted-orphan-drug-designation-for-clr-131-to-treat-neuroblastoma-idUSFWN1R10LO",
    "ord_in_thread": 0,
    "title": "BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 43 PM / Updated 11 minutes ago BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma Reuters Staff March 19 (Reuters) - Cellectar Biosciences Inc: * CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA * ‍CELLECTAR EXPECTS TO INITIATE THIS STUDY DURING Q2 OF 2018​ Source text for Eikon:  ",
    "published": "2018-03-19T14:40:00.000+02:00",
    "crawled": "2018-03-19T15:00:16.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "bioscience",
        "get",
        "granted",
        "orphan",
        "drug",
        "designation",
        "clr",
        "treat",
        "neuroblastoma",
        "reuters",
        "staff",
        "march",
        "reuters",
        "cellectar",
        "bioscience",
        "inc",
        "cellectar",
        "bioscience",
        "granted",
        "orphan",
        "drug",
        "designation",
        "clr",
        "treat",
        "neuroblastoma",
        "expects",
        "initiate",
        "study",
        "q2",
        "source",
        "text",
        "eikon"
    ]
}